Sherbrooke Park Advisers LLC Biocryst Pharmaceuticals Inc Transaction History
Sherbrooke Park Advisers LLC
- $436 Billion
- Q3 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 27,494 shares of BCRX stock, worth $212,253. This represents 0.05% of its overall portfolio holdings.
Number of Shares
27,494Holding current value
$212,253% of portfolio
0.05%Shares
3 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$157 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$154 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$91.6 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$70.1 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$68.3 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.44B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...